ABBVAbbVieRunning, no new patients
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 130 (final count)
- Started
- Sep 21, 2023
- Main results expected
- Nov 2026
- Fully finished
- Nov 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Best Overall Response (BOR) per Investigator
Measured over: Through Study Completion, Up to Approximately 27 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05822752 · record last updated 2025-08-14 · checked 2026-11-09 15:47 UTC